Flow Cytometry - Leukemia/Lymphoma immunophenotyping
Test Catalog Information
Test Catalog Synonyms | |
EPIC Synonyms |
markers immunophenotype |
Cerner Primary Mnemonic | HLX Flow Cytometry Request CASE |
EPIC Display Name | Flow Cytometry - Leukemia/Lymphoma immunophenotyping |
Allscripts (AEHR) Order Name | Flow Cytometry |
Sunrise Clinical Manager (SCM) Order Name | Flow Cytometry |
EPIC Inpatient Orderable | Yes |
EPIC Outpatient Orderable | Yes |
Cerner Results | |
Clinical Info |
Phenotyping by flow cytometry can aid in the evaluation of hematopoietic neoplasms in specimens including bone marrow, whole blood, tissue, or fluid. It facilitates lineage detection (i.e. B vs T vs myeloid) and in conjunction with morphologic and other ancillary findings, can provide a confirmatory diagnosis or differential diagnoses. Phenotyping may aid in monitoring response to therapy in individuals with an established diagnosis of hematopoietic neoplasms. Markers are analyzed as needed, based on clinical evidence and history, as an initial screening panel. Additional markers are selected based on pathologist interpretation of the screening panel results to fully characterize any abnormalities identified by the screening panel. Antigens included: T/NK cell: CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, TRCB-1, CD30, TCR gamma-delta, TCR alpha-beta, CD279, CD26 B cell: CD10, CD19, CD20, CD22, CD23, CD103, CD200, kappa, lambda, CD79b, FMC-7, CD103, cCD79a, cCD22 Myeloid/monocyte: CD11b, CD13, CD14, CD16, CD15, CD33, CD64, CD11b, CD117, myeloperoxidase, CD34 Plasma cell: CD138, CD38, cytoplasmic kappa and lamda, CD27, CD81, CD56, CD117 Miscellaneous: CD11c, CD123, CD41, CD61, CD71, TdT, CD36, CD42b, CD45, HLA-DR, TdT, CRLF-2 Poor cell viability may adversely affect antigens and compromise result accuracy and reliability. |
Specimen Type |
Blood, Body Fluid, CSF, Bone Marrow, Tissue |
Container |
Green-top (sodium heparin) tube or Lavender (EDTA) tube |
Collection Instructions |
Contact the Tumor Marker (Flow Cytometry) Laboratory CFAMFlow@northwell.edu for collection instructions and consultation on selection of test(s). Test for PNH is performed at Long island Jewish Flow Lab 718-470-3035 and requires two Lavender (EDTA) tubes - Done on Peripheral Blood Samples Only. Immediate Delivery to the Lab is recommended. Submit only 1 of the following specimens: Blood - Green-top (sodium heparin) tube or Lavender top (EDTA) tube. Recommended Amount: 3 mL whole blood (1 mL min) Transport Temperature: Room Temperature Collection Instructions: Deliver specimen to laboratory within 12 Hours Note: 1. Indicate blood on request form . 2. Comment Rituximab Sensitivity on form Bone Marrow - Obtain 3 mL of bone marrow in a green-top (sodium heparin) tube or lavender top (EDTA) tube. Forward promptly at ambient temperature. Deliver specimen to laboratory within 12 Hours Note: 1. Indicate bone marrow on request form. 2. Label with Rituximab Sensitivity. Bone Marrow aspirate smears (recommend 4-6) must accompany all bone marrow specimens. Include Peripheral Blood Smear whenever possible. CAUTION: If sending unstained slides as part of biopsy kit, please package slides separately outside of the biopsy box. Do not freeze. CSF - 3mL desired in sterile container at Room Temperature. Do not freeze. Deliver to lab immediately is recommended. If needed, Refrigerate to maintain 2-8°C. Tissue - Obtain tissue in sterile Container and indicate the source - 0.5cm3 recommended. Recommended Storage medium - RPMI 1640 but Saline can be substituted. Transfer at Room Temperature. Do not freeze. Deliver to the lab immediately. If needed, Refrigerate to maintain 2-8°C. Body Fluid - Obtain 3-5mL Body Fluid in sterile container. Indicate Fluid type on the sample. Transfer at Room Temperature. Deliver to lab immediately is recommended. If needed, Refrigerate to maintain 2-8°C. |
Transport Instructions |
RoomTemperature |
Specimen Stability |
Immediate delivery to the lab is recommended |
Methodology |
Flow Cytometry at minimum includes for a B-cell work-up - CD5, CD10, CD19, CD20, CD23, CD38, CD200 kappa Light chain, Lambda Light chain and CD45. For a T-cell CD57, CD56, CD7, CD8, CD2, CD4, CD3, CD5, CD16 and CD45. For at minimum Leukemia work-up CD13, CD33, CD34, CD117 and CD45. For a Plasma Cell work-up, at minimum - CD38, CD138, cytoplasmic Kappa, cytoplasmic Lambda and CD45. Additional markers may be performed based on diagnosis and cell count. |
Days Performed |
Laboratory is open Mondays through Fridays 7:00AM to 12:00AM. All testing is available during these hours. Limited testing is available on Saturdays from 8AM-4PM. Laboratory is closed on Sundays and Legal Holidays – New Year’s, Martin Luther King Jr, President’s, Memorial, Independence, Labor, Thanksgiving and Christmas Day. |
Performing Laboratory |
Northwell Health Laboratories |
CPT |
86356 |
PDM |
5299996 |
Desired Epic Build Flow Cytometry - Leukemia/Lymphoma immunophenotyping
Cerner Primary Mnemonic: | HLX Flow Cytometry Request CASE |
PDM | 5299996 |
Informatics - Workgroup | Flow Cytometry |
Synonyms * | markers immunophenotype |
Display Name * | Flow Cytometry - Leukemia/Lymphoma immunophenotyping |
Order Entry Specimen Sources * | |
Order Entry Specimen Types |
Aspirate
Body Fluid
Tissue
|
Specimen Navigator Specimen Types | |
Specimen Navigator Specimen Sources | |
Specimen Navigator Short Name | |
Ordering info (EPIC SmartText) | Phenotyping by flow cytometry can aid in the evaluation of hematopoietic neoplasms in specimens including bone marrow, whole blood, tissue, or fluid. It facilitates lineage detection (i.e. B vs T vs myeloid) and in conjunction with morphologic and other ancillary findings, can provide a confirmatory diagnosis or differential diagnoses. Phenotyping may aid in monitoring response to therapy in individuals with an established diagnosis of hematopoietic neoplasms. Markers are analyzed as needed, based on clinical evidence and history, as an initial screening panel. Additional markers are selected based on pathologist interpretation of the screening panel results to fully characterize any abnormalities identified by the screening panel. Antigens included: T/NK cell: CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD56, CD57, TRCB-1, CD30, TCR gamma-delta, TCR alpha-beta, CD279, CD26 B cell: CD10, CD19, CD20, CD22, CD23, CD103, CD200, kappa, lambda, CD79b, FMC-7, CD103, cCD79a, cCD22 Myeloid/monocyte: CD11b, CD13, CD14, CD16, CD15, CD33, CD64, CD11b, CD117, myeloperoxidase, CD34 Plasma cell: CD138, CD38, cytoplasmic kappa and lamda, CD27, CD81, CD56, CD117 Miscellaneous: CD11c, CD123, CD41, CD61, CD71, TdT, CD36, CD42b, CD45, HLA-DR, TdT, CRLF-2 Poor cell viability may adversely affect antigens and compromise result accuracy and reliability. |
IP Orderable | Yes |
OP Orderable | Yes |
AOEs * | |
AP AOEs | |
Special History | No |
Build Comments | |
Filter * | pathology |
Procedure Category Change | |
Cerner Results |
Current Actual EPIC Build as of 10/28/2024
Procedure Id | 72348 | ||||||||||||||||||||||||
Pdm | 5299996 | ||||||||||||||||||||||||
Order Display Name | Flow Cytometry - Leukemia/Lymphoma immunophenotyping | ||||||||||||||||||||||||
Procedure Name | FLOW CYTOMETRY | ||||||||||||||||||||||||
Procedure Master Number | LAB1729 | ||||||||||||||||||||||||
Short Procedure Name | Flow Cytometry | ||||||||||||||||||||||||
Category Code | 15.0 | ||||||||||||||||||||||||
Category Code Record Name | LAB CYTOGENETICS ORDERABLES | ||||||||||||||||||||||||
Synonyms | MARKERS IMMUNOPHENOTYPE | ||||||||||||||||||||||||
Clinically Active | Yes | ||||||||||||||||||||||||
Orderable | Yes | ||||||||||||||||||||||||
Performable | Yes | ||||||||||||||||||||||||
Filter Genomics | Not a Genomics Procedure | ||||||||||||||||||||||||
Reference Link Url | https://labs.northwell.edu/epic/test/72348 | ||||||||||||||||||||||||
Ordering Instructions | |||||||||||||||||||||||||
Default Specimen Type | |||||||||||||||||||||||||
Specimen Type Pick List | Cerebrospinal Fluid Tissue Blood Bone Marrow Other Apheresis Product | ||||||||||||||||||||||||
Specimen Type List | |||||||||||||||||||||||||
Op Specimen Type List | |||||||||||||||||||||||||
Specimen Source Pick List | Cerebrospinal Fluid Bone Marrow Misc | ||||||||||||||||||||||||
Specimen Source Default - Male | |||||||||||||||||||||||||
Specimen Source Default - Female | |||||||||||||||||||||||||
Specimen Source List | Cerebrospinal Fluid Bone Marrow Other | ||||||||||||||||||||||||
Op Specimen Source List | |||||||||||||||||||||||||
Ip Lab Test Components For Report | |||||||||||||||||||||||||
Op Lab Test Components For Report | |||||||||||||||||||||||||
Order Questions | ["3045300170", "3045300171", "3045300173"] | ||||||||||||||||||||||||
Order Questions Record Name | NH IP HOME COLLECT DATE NH IP HOME COLLECT DAYS NH IP HOME COLLECT MEDICALLY NECESSARY | ||||||||||||||||||||||||
Inpatient Order Questions | [] | ||||||||||||||||||||||||
Inpatient Order Questions Record Name | |||||||||||||||||||||||||
Order Specific Question Override | Yes | ||||||||||||||||||||||||
Inpatient Question Override | Yes | ||||||||||||||||||||||||
Location Restrict List Ip | |||||||||||||||||||||||||
Location Restrict List Ip Record Name | |||||||||||||||||||||||||
Location Restrict List Include Ip | |||||||||||||||||||||||||
Location Restrict List Op | |||||||||||||||||||||||||
Location Restrict List Op Record Name | |||||||||||||||||||||||||
Location Restrict List Includes Op | |||||||||||||||||||||||||
Edp Amb Order Specific Questions Record Name | NH IP PATIENT COMPLETED CONSENT | ||||||||||||||||||||||||
Edp Ip Order Specific Questions Record Name | NH IP PATIENT COMPLETED CONSENT | ||||||||||||||||||||||||
Edp Ip Specimen Source | |||||||||||||||||||||||||
Edp Op Specimen Source | |||||||||||||||||||||||||
Edp Ip Specimen Type | |||||||||||||||||||||||||
Edp Op Specimen Type | |||||||||||||||||||||||||
Derived Edp Ip Buttons S | |||||||||||||||||||||||||
Derived Edp Ip Buttons T | |||||||||||||||||||||||||
Derived Edp Op Buttons S | |||||||||||||||||||||||||
Derived Edp Op Buttons T | |||||||||||||||||||||||||
Ip Orderable | 1 | ||||||||||||||||||||||||
Op Orderable | 1 | ||||||||||||||||||||||||
EPIC OP AOEs
| |||||||||||||||||||||||||
EPIC IP AOEs | |||||||||||||||||||||||||
EPIC Components (results) |